A new use for HMG-CoA reductase inhibitors is provided. In the instant
invention, HMG-CoA reductase inhibitors are found to upregulate
endothelial cell Nitric Oxide Synthase activity through a mechanism other
than preventing the formation of oxidative-LDL. As a result, HMG-CoA
reductase inhibitors are useful in treating or preventing conditions that
result from the abnormally low expression and/or activity of endothelial
cell Nitric Oxide Synthase. Such conditions include pulmonary
hypertension, ischemic stroke, impotence, heart failure, hypoxia-induced
conditions, insulin deficiency, progressive renal disease, gastric or
esophageal motility syndrome, etc. Subjects thought to benefit mostly
from such treatments include nonhyperlipidemics and
nonhypercholesterolemics, but not necessarily exclude hyperlipidemics and
hypercholesterolemics.
Um uso novo para inibidores do reductase de HMG-CoA é fornecido. Na invenção instantânea, os inibidores do reductase de HMG-CoA são encontrados à atividade nitric de Synthase do óxido da pilha endothelial do upregulate através de um mecanismo à excepção de impedir a formação de oxidative-LDL-LDL. Em conseqüência, os inibidores do reductase de HMG-CoA são úteis em tratar ou em impedir as circunstâncias que resultam da expressão e/ou da atividade anormalmente baixas do óxido nitric Synthase da pilha endothelial. Tais circunstâncias incluem o hypertension pulmonary, curso isquêmico, impotence, falha de coração, circunstâncias hypoxia-induzidas, deficiência do insulin, doença renal progressiva, syndrome gastric ou esophageal do motility, etc.. O pensamento dos assuntos ao benefício na maior parte de tais tratamentos inclui o nonhyperlipidemics e o nonhypercholesterolemics, mas para excluir não necessariamente o hyperlipidemics e o hypercholesterolemics.
